{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
Eur J Heart Fail. Oct 2022;24(10):1967-1977.: Phase 2 Human clinical trial Completed Shock, Cardiogenic/etiology
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Etiocholanone is an androstane neurosteroid. Etiocholanone potentiates GABA-A receptor currents and exerts anticolvunsant properties in rodents. Etiocholanolone demostrates pyrogenic properties.
Status:
Investigational
Source:
JAN:MONATEPIL MALEATE [JAN]
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Targets:
Conditions:
Monatepil is a calcium antagonist that, as do existing calcium antagonists, inhibits the influx of extracellular Ca 2 + through voltage-dependent Ca 2 + channels. It is a new type of antihypertensive agent. Its unique chemical structure was specially designed with intrinsic calcium antagonist and a1 -adrenoceptor-blocking moieties, creating a dual mechanism of action. Positive effects on plasma lipid metabolism are derived from the a1 -adrenoceptor-blocking activity and the antiatherosclerotic effect derives from the calcium antagonist properties. The novel structure of monatepil produces a slow onset of action and a long-lasting antihypertensive effect in experimental animals.
Class (Stereo):
CHEMICAL (RACEMIC)
Targets:
Conditions:
Lemildipine is a 1,4-dihydropyridine calcium channel blocker which is under phase III development by Banyu (Merck and Co), in Japan, for its potential to treat hypertension and cerebrovascular ischemia. In one study, involving five patients with essential hypertension accompanied by cerebrovascular disorder, lemildipine, administered orally at doses of 5 to 20 mg/day, significantly lowered blood pressure and increased cerebral blood flow. Another study in 31 patients with essential hypertension demonstrated that lemildipine has significant pressure lowering effects without affecting serum lipids. Worldwide rights to market the drug have been assigned to Kowa in Japan.
Status:
Investigational
Source:
INN:carmoxirole [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Carmoxirole is a dopamine D2 receptor agonist with limited central activity that modulates sympathetic activation and subsequently reduces pre-load and afterload in animals. It was shown, that carmoxirole induced beneficial effects on hemodynamic and neurohumoral parameters in heart failure. In addition, experimental evidence showed that carmoxirole lowered blood pressure in various models of hypertension mainly or exclusively through inhibition of noradrenaline release from sympathetic nerve endings. That effect of carmoxirole was mediated by presynaptic dopamine receptors with the characteristic that release inhibition was restricted to low rates of sympathetic nerve discharge.
Class (Stereo):
CHEMICAL (RACEMIC)
Targets:
Conditions:
Iganidipin is a new dihydropiridynic derivative of calcium antagonist. It is the only currently available calcium antagonist in the form of ophthalmic solution. Its topical administration increases ipsilateral optic nerve head blood flow in rabbits and monkeys and inhibits the contraction of blood vessels induced by endothelin -1. Iganidipin is also used for treat Angina pectoris and Hypertension.
Status:
Investigational
Source:
NCT04905654: Not Applicable Human clinical trial Completed Migraine with Aura
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Cromakalim is an ATP-sensitive potassium (KATP) channel opener, which was studied for the treatment of gastric ulcer, hypertension and preventing a cardiomyopathy. But the development of this drug was discontinued due to heart lesions found in monkey chronic toxicity studies.
Status:
Investigational
Source:
Acta Psychiatr Scand. Jul 1977;56(1):57-61.: Not Applicable Human clinical trial Completed Dyskinesia, Drug-Induced
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Fusaric acid (J-butylpicolinic acid) is a fungal toxin with low to moderate toxicity synthesized by some Fusurium species which cause infections in cereal grains and other agricultural commodities. It may potentiate the effects of other Fusurium toxins. Fusaric acid is a potent inhibitor of DNA synthesis. Fusaric acid has potent anti-proliferative activity in vitro on various normal and cancer cell lines and suggest that it exhibits some cytotoxic specificity for growing and confluent colorectal adenocarcinoma and mammary adenocarcinoma cell lines. Fusaric acid is known as a potent dopamine-beta-hydroxylase inhibitor of high specificity. Fusaric acid calcium salt elicited the hypotensive response primarily through the reduction of total peripheral vascular resistance index.
Status:
Other
Class (Stereo):
CHEMICAL (RACEMIC)
Conditions:
PD123319 is a potent, selective AT2 angiotensin II receptor antagonist with IC50 of 34 nM.PD123319 had been in phase I clinical trials by Pfizer for the treatment of hypertension. However, this research has been discontinued.
Status:
Other
Class (Stereo):
CHEMICAL (RACEMIC)
Targets:
Conditions:
LY-272015 is an antagonist at serotonin 5-HT2B receptor. LY-272015 exerts antihypertensive action in animal models.
The stem, wood and bark of Uncaria kawakamii contain the two isomeric alkaloids, Uncarine A and Uncarine B, the highest proportion of alkaloids (1.48%) occurring in the bark. Uncarine A caused a marked decrease of systolic and diastolic pressures in renal or spontaneously hypertensive conscious rats, but not in normotensive rats. During the period of hypotensive action, the heart rate was increased. No effect on the noradrenaline content of the heart or on the pressor responses to noradrenaline, angiotensin II, or sympathetic stimulation was observed. The concentrations of plasma noradrenaline and adrenaline in the spontaneously hypertensive rat were markedly increased when the blood pressure was lowered. Uncarine A apparently reduces the blood pressure of hypertensive rats by a mechanism different from that of currently used antihypertensive agents. The site of action could be the central nervous system.